Company: ARWR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001628280-25-004634
Chunk: 16

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
 in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (“RNAi”) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company’s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. The following table presents the Company’s current pipeline: Therapeutic AreaNameStageProduct RightsCardiometabolicplozasiranPhase 3ArrowheadzodasiranPhase 2bArrowheadolpasiranPhase 3AmgenPulmonaryARO-RAGEPhase 1/2aArrowheadARO-MMP7Phase 1/2aArrowheadLiverGSK-4532990Phase 2bGSKfazirsiranPhase 3Takeda and Arrowheaddaplusiran/tomligisiranPhase 2GSKARO-PNPLA3Phase 1ArrowheadARO-C3Phase 1/2aArrowheadARO-CFBPhase 1/2aArrowheadARO-INHBEPhase 1/2aArrowheadMuscleARO-DUX4Phase 1/2aArrowheadARO-DM1Phase 1/2aArrowheadCentral Nervous System (CNS)ARO-ATXN2Phase 1/2aArrowheadThe Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company’s principal executive offices are located in Pasadena, California.During the first quarter of fiscal 2025, the Company continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: •Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on November 16, 2024, which was accepted for filing on January 17, 2025. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting;•Entered into a global and collaboration agreement with Sarepta Therapeutics, Inc. The Company received $325.0 million